COMMUNIQUÉS West-GlobeNewswire

Epilepsy Foundation Introduces New Mission & Vision Statements at National Leadership Conference

23/09/2024 - 14:00

The New Statements Guide the Foundation’s 2025-2028 Strategic Plan BOWIE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- After more than 50 years of operating under the same mission statement, the Epilepsy Foundation unveiled [...]

Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference

23/09/2024 - 14:00

CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]

Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference

23/09/2024 - 14:00

LONDON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics , formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at Chardan’s 8 th Annual [...]

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)

23/09/2024 - 14:00

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has [...]

Blue Cross and Blue Shield of Minnesota Launches New Center to Combat Racial and Health Inequities

23/09/2024 - 14:00

Health plan focuses on evolving community needs while renewing longstanding commitment to address inequities, promote greater health EAGAN, Minn., Sept. 23, 2024 (GLOBE NEWSWIRE) -- As an extension and evolution of the [...]

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23/09/2024 - 14:00

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of Neuroblastoma Study Illustrates Potential to Activate the Immune System Even in Cancers That Have [...]

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

23/09/2024 - 14:00

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a [...]

MedCerts Launches Certified Cing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals

23/09/2024 - 14:00

New certification program features generative and conversational AI developed in-house, setting a new standard in healthcare training LIVONIA, Mich., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Offering a vital solution for [...]

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

23/09/2024 - 14:00

WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly [...]

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

23/09/2024 - 14:00

– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will [...]

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

23/09/2024 - 14:00

Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232 SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical- [...]

Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

23/09/2024 - 14:00

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to [...]

Novo Nordisk A/S - share repurchase programme

23/09/2024 - 13:56

Bagsværd, Denmark, 23 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

23/09/2024 - 13:35

- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE [...]

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

23/09/2024 - 13:30

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones [...]

VitalHub Announces Strategic Hire to Accelerate Corporate Growth

23/09/2024 - 13:30

TORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) ("VitalHub" or the “Company”) is pleased to announce the addition of Christian Sgro as Head of Investor Relations and Mergers and [...]

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

23/09/2024 - 13:30

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones [...]

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

23/09/2024 - 13:30

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified [...]

Nova Leap Health Corp. to Present at the Planet MicroCap Showcase

23/09/2024 - 13:29

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]